ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into an exclusive worldwide license agreement (the "Agreement") with MOR Research Applications Ltd. ("MOR"), the technology transfer company of Clalit Health Services and Yeda Research, the technology transfer company of the Weizmann Institute of Science and Development Co. Ltd. ("Yeda"), for proprietary artificial intelligence-driven...
2026-07-20 6:00 AM EDT
ALZAI Health Corp. Announces Validation of Its AI-Driven Alzheimers Disease Risk Screening Solution on Large-Scale U.S. Patient Data
Toronto, Ontario--(Newsfile Corp. - July 6, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce the validation of its proprietary artificial intelligence-driven Alzheimer's disease risk identification models using a large-scale U.S. longitudinal healthcare dataset, representing a significant milestone in the Company's potential U.S. commercialization. The validation demonstrated that ALZAI's risk-stratification models achieved performance on-par with...
2026-07-06 6:00 AM EDT
Alzai Health Corp. Signs Strategic U.S. Commercialization Agreement with Centauri Health Solutions to Advance AI-Driven Alzheimer's Risk Identification
Toronto, Ontario--(Newsfile Corp. - July 2, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into a strategic teaming agreement (the "Agreement") with Centauri Health Solutions ("Centauri"), a leading U.S. healthcare technology company serving 60 million members through advanced mission-critical technology, data intelligence, and engagement solutions delivered to U.S. health plans, healthcare providers and health systems. Under the...
2026-07-02 6:49 AM EDT